Revealing the molecular mechanism of colorectal cancer by establishing LGALS3‑related protein-protein interaction network and identifying signaling pathways

Han,Lu; Wu,Zhixiong; Zhao,Qicheng

doi:10.3892/ijmm.2014.1620

Revealing the molecular mechanism of colorectal cancer by establishing LGALS3‑related protein-protein interaction network and identifying signaling pathways

Authors:
- Lu Han
- Zhixiong Wu
- Qicheng Zhao
View Affiliations

Affiliations: Economics Division, School of Social and International Studies, University of Bradford, Bradford BD7 1DP, UK, Department of Oncology, Chongqing Cancer Institute, Shapingba, Chongqing 400030, P.R. China
Published online on: January 8, 2014 https://doi.org/10.3892/ijmm.2014.1620
Pages: 581-588

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

LGALS3 plays a role in colorectal cancer, however, the detailed molecular mechanism remains to be determined, while signaling pathways provide valuable information for understanding the underlying mechanism of the cancer. The purpose of this study was to explore the roles of LGALS3 and signaling pathways in the pathogenesis of colorectal cancer. In this study, microarray data GSE8671 were downloaded from the Gene Expression Omnibus database and differentially expressed genes (DEGs) in colorectal cancer were identified by Significant Analysis of Microarray. Gene ontology (GO) analysis was performed on the top 500 upregulated and 500 downregulated genes using DAVID. The signaling pathways were predicted by the signaling pathway impact analysis (SPIA) with pGFdr<0.05 and transcription factors were identified by TFats. The LGALS3‑related protein-protein interaction network (PPI) was established by STRING and Cytoscape. In total, 6,593 upregulated and 5,897 downregulated DEGs were identified and 41 downregulated genes, including CLND8 and CLND23 were enriched in cell adhesion. In addition, 21 pathways, such as the cell cycle, p53 signaling pathway and NF-κB signaling pathway, were selected. MYC and TCF7L2 were found to be activated while FOXO3 was suppressed in colorectal cancer. Eight downregulated and 10 upregulated genes were identified in the LGALS3 PPI network. Results of the present study shed new light on the molecular mechanism of colorectal cancer and these findings have the potential to be used in colorectal cancer treatment.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Atkin WS, Edwards R, Kralj-Hans I, et al: Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 375:1624–1633. 2010. View Article : Google Scholar : PubMed/NCBI
3	Grady WM and Carethers JM: Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 135:1079–1099. 2008. View Article : Google Scholar : PubMed/NCBI
4	Leggett B and Whitehall V: Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 138:2088–2100. 2010. View Article : Google Scholar : PubMed/NCBI
5	Stratton MR, Campbell PJ and Futreal PA: The cancer genome. Nature. 458:719–724. 2009. View Article : Google Scholar
6	Lanza G, Ferracin M, Gafa R, et al: mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer. 6:542007. View Article : Google Scholar : PubMed/NCBI
7	Jones S, Zhang X, Parsons DW, et al: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 321:1801–1806. 2008. View Article : Google Scholar : PubMed/NCBI
8	Lustig B and Behrens J: The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol. 129:199–221. 2003.PubMed/NCBI
9	Maxwell PH, Pugh CW and Ratcliffe PJ: Activation of the HIF pathway in cancer. Curr Opin Genet Dev. 11:293–299. 2001. View Article : Google Scholar : PubMed/NCBI
10	Sankpal UT, Goodison S, Abdelrahim M and Basha R: Targeting SP1 transcription factor in prostate cancer therapy. Med Chem. 7:518–525. 2011. View Article : Google Scholar : PubMed/NCBI
11	Tomlins SA, Rhodes DR, Perner S, et al: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 310:644–648. 2005. View Article : Google Scholar : PubMed/NCBI
12	Yang Y, Goldstein BG, Chao HH and Katz JP: KLF4 and KLF5 regulate proliferation, apoptosis and invasion in esophageal cancer cells. Cancer Biol Ther. 4:1216–1221. 2005. View Article : Google Scholar : PubMed/NCBI
13	Dolcet X, Llobet D, Pallares J and Matias-Guiu X: NF-κB in development and progression of human cancer. Virchows Arch. 446:475–482. 2005.
14	Sabates-Bellver J, Van Der Flier LG, De Palo M, et al: Transcriptome profile of human colorectal adenomas. Mol Cancer Res. 5:1263–1275. 2007. View Article : Google Scholar
15	Bresalier RS, Mazurek N, Sternberg LR, et al: Metastasis of human colon cancer is altered by modifying expression of the β-galactoside-binding protein galectin 3. Gastroenterology. 115:287–296. 1998.PubMed/NCBI
16	Zhao Q, Guo X, Nash GB, et al: Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface. Cancer Res. 69:6799–6806. 2009. View Article : Google Scholar : PubMed/NCBI
17	Zhao Q, Barclay M, Hilkens J, et al: Research interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Mol Cancer. 9:1542010. View Article : Google Scholar : PubMed/NCBI
18	Irizarry RA, Hobbs B, Collin F, et al: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 4:249–264. 2003. View Article : Google Scholar
19	Tusher VG, Tibshirani R and Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 98:5116–5121. 2001. View Article : Google Scholar : PubMed/NCBI
20	Harris M, Clark J, Ireland A, et al: The gene ontology (GO) database and informatics resource. Nucleic Acids Res. 32:D258–D261. 2004.PubMed/NCBI
21	Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2008.PubMed/NCBI
22	Tarca AL, Draghici S, Khatri P, et al: A novel signaling pathway impact analysis. Bioinformatics. 25:75–82. 2009. View Article : Google Scholar : PubMed/NCBI
23	Essaghir A, Toffalini F, Knoops L, Kallin A, van Helden J and Demoulin JB: Transcription factor regulation can be accurately predicted from the presence of target gene signatures in microarray gene expression data. Nucleic Acids Res. 38:e1202010. View Article : Google Scholar : PubMed/NCBI
24	von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P and Snel B: STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 31:258–261. 2003.PubMed/NCBI
25	Kohl M, Wiese S and Warscheid B: Cytoscape: Software for visualization and analysis of biological networks. Data Mining in Proteomics. Hamacher M, Eisenacher M and Stephan C: Humana Press; pp. 291–303. 2011, PubMed/NCBI
26	Steeg PS: Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 12:895–904. 2006. View Article : Google Scholar : PubMed/NCBI
27	Cox DG, Hankinson SE and Hunter DJ: Polymorphisms of the AURKA (STK15/Aurora Kinase) gene and breast cancer risk (United States). Cancer Causes Control. 17:81–83. 2006. View Article : Google Scholar : PubMed/NCBI
28	Couch FJ, Sinilnikova O, Vierkant RA, et al: AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev. 16:1416–1421. 2007. View Article : Google Scholar : PubMed/NCBI
29	Zhu X, Mao Z, Na Y, Guo Y, Wang X and Xin D: Significance of pituitary tumor transforming gene 1 (PTTG1) in prostate cancer. Anticancer Res. 26:1253–1259. 2006.PubMed/NCBI
30	Gorynia S, Bandeiras TM, Pinho FG, et al: Structural and functional insights into a dodecameric molecular machine - the RuvBL1/RuvBL2 complex. J Struct Biol. 176:279–291. 2011. View Article : Google Scholar : PubMed/NCBI
31	Carattino MD, Prakasam HS, Ruiz WG, et al: Bladder filling and voiding affect umbrella cell tight junction organization and function. Am J Physiol Renal Physiol. Jul 24–2013.(Epub ahead of print).
32	Osunkoya AO, Cohen C, Lawson D, Picken MM, Amin MB and Young AN: Claudin-7 and claudin-8: immunohistochemical markers for the differential diagnosis of chromophobe renal cell carcinoma and renal oncocytoma. Hum Pathol. 40:206–210. 2009. View Article : Google Scholar : PubMed/NCBI
33	Katoh M and Katoh M: CLDN23 gene, frequently down-regulated in intestinal-type gastric cancer, is a novel member of CLAUDIN gene family. Int J Mol Med. 11:683–689. 2003.PubMed/NCBI
34	Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med. 10:789–799. 2004. View Article : Google Scholar : PubMed/NCBI
35	Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 9:153–166. 2009. View Article : Google Scholar : PubMed/NCBI
36	Sherr CJ: Cancer cell cycles. Science. 274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI
37	Maruyama K, Kawagoe T, Kondo T, Akira S and Takeuchi O: TRAF family member-associated NF-κB activator (TANK) is a negative regulator of osteoclastogenesis and bone formation. J Biol Chem. 287:29114–29124. 2012.
38	O’neill LA and Kaltschmidt C: NF-κB: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci. 20:252–258. 1997.
39	Barnes PJ: Nuclear factor-κB. Int J Biochem Cell Biol. 29:867–870. 1997.
40	Scartozzi M, Bearzi I, Pierantoni C, et al: Nuclear factor-κB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol. 25:3930–3935. 2007.
41	Darnell JE Jr: Transcription factors as targets for cancer therapy. Nat Rev Cancer. 2:740–749. 2002. View Article : Google Scholar : PubMed/NCBI
42	Bièche I, Laurendeau I, Tozlu S, et al: Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res. 59:2759–2765. 1999.
43	Le Floch N, Rivat C, De Wever O, et al: The proinvasive activity of Wnt-2 is mediated through a noncanonical Wnt pathway coupled to GSK-3β and c-Jun/AP-1 signaling. FASEB J. 19:144–146. 2005.PubMed/NCBI
44	Kojima T, Shimazui T, Horie R, et al: FOXO1 and TCF7L2 genes involved in metastasis and poor prognosis in clear cell renal cell carcinoma. Genes Chromosomes Cancer. 49:379–389. 2010.PubMed/NCBI
45	Arden KC: Multiple roles of FOXO transcription factors in mammalian cells point to multiple roles in cancer. Exp Gerontol. 41:709–717. 2006. View Article : Google Scholar : PubMed/NCBI
46	Roy S, Srivastava R and Shankar S: Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal. 5:102010. View Article : Google Scholar : PubMed/NCBI
47	John A and Tuszynski G: The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res. 7:14–23. 2001. View Article : Google Scholar : PubMed/NCBI